Patents by Inventor John Hayslip

John Hayslip has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSING REGIMENS FOR USE IN TREATING MYELOFIBROSIS AND MPN-RELATED DISORDERS WITH NAVITOCLAX
    Publication number: 20230019186
    Abstract: The invention described herein relates to methods for treating a human subject with myelofibrosis or an MPN-related disorder, comprising administering navitoclax to the subject optionally in combination with ruxolitinib.
    Type: Application
    Filed: February 15, 2022
    Publication date: January 19, 2023
    Inventors: John Hayslip, Leanne M. Holes, Sven Mensing, Silpa Nuthalapati
  • VENETOCLAX DOSING REGIMENS FOR USE IN TREATING MYELODYSPLASTIC SYNDROMES IN COMBINATION WITH AZACITIDINE
    Publication number: 20220378811
    Abstract: The invention described herein relates to therapeutic dosing regimens comprising administering venetoclax in combination with azacitidine for treating myelodysplastic syndromes (MDS).
    Type: Application
    Filed: May 10, 2022
    Publication date: December 1, 2022
    Applicant: ABBVIE INC.
    Inventors: John HAYSLIP, Steve H. KYE, William B. AINSWORTH
  • VENETOCLAX DOSING REGIMENS FOR USE IN TREATING MYELODYSPLASTIC SYNDROMES IN COMBINATION WITH A CYP3A INHIBITOR AND AZACITIDINE
    Publication number: 20220370481
    Abstract: The invention described herein relates to therapeutic dosing regimens comprising administering venetoclax in combination with azacitidine and a CYP3A inhibitor for treating myelodysplastic syndromes (MDS).
    Type: Application
    Filed: May 10, 2022
    Publication date: November 24, 2022
    Applicant: ABBVIE INC.
    Inventors: John HAYSLIP, Steve H. KYE, Ahmed SALEM, Jiuhong ZHA
  • Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax
    Patent number: 11285159
    Abstract: The invention described herein relates to methods for treating a human subject with myelofibrosis or an MPN-related disorder, comprising administering navitoclax to the subject optionally in combination with ruxolitinib.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: March 29, 2022
    Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: John Hayslip, Leanne M. Holes, Sven Mensing, Silpa Nuthalapati
  • DOSING REGIMENS FOR USE IN TREATING MYELOFIBROSIS AND MPN-RELATED DISORDERS WITH NAVITOCLAX
    Publication number: 20210128573
    Abstract: The invention described herein relates to methods for treating a human subject with myelofibrosis or an MPN-related disorder, comprising administering navitoclax to the subject optionally in combination with ruxolitinib.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Inventors: John Hayslip, Leanne M. Holes, Sven Mensing, Silpa Nuthalapati